Tenderwize
Back to tender search

Non-exclusive Drug Discount Agreement for Nilotinib

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jul 31, 2027 · 296 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No minimum purchase guarantees; actual demand depends on prescription behavior and may be low.

The buyer may terminate the procedure early if exclusive agreements are concluded, ending all non-exclusive agreements.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jul 31, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of pharmaceutical products containing Nilotinib (ATC L01EA03) to AOK PLUS insured members in Saxony and Thuringia
  • Non-exclusive discount agreement under §130a Abs. 8 SGB V
Show full summary

This tender is a non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs. 8 SGB V for the active substance Nilotinib (ATC L01EA03), conducted as an Open-House model by AOK PLUS for Saxony and Thuringia. The procedure is voluntary transparency publication, not a formal procurement under EU directive. Any qualified pharmaceutical entrepreneur can join during the participation period. No guaranteed volumes, no exclusivity, and the agreement ends by 31 July 2027 unless terminated earlier due to exclusive agreements. The estimated value is not disclosed. Submission is electronic via DTVP portal; first deadline 7 July 2026, with subsequent periodic deadlines.

Risks

No minimum purchase guarantees; actual demand depends on prescription behavior and may be low.

The buyer may terminate the procedure early if exclusive agreements are concluded, ending all non-exclusive agreements.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered medicines

Eligibility

  • Must submit a self-declaration on exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)

Administrative

  • Must submit a self-declaration on Russia sanctions (Eigenerklärung Russlandsanktionen)

Requirements may be incomplete.

Award Criteria

Lot 1

Price: The discount is the key criterion but not formally weighted; acceptance is based on meeting participation requirements and accepting the terms.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Nilotinib

Open-House model for concluding non-exclusive rebate agreements for Nilotinib (excluding Nilotinib dispersed in applesauce unless patent-protected). The agreement is open to all interested pharmaceutical entrepreneurs meeting the requirements. No minimum purchase quantities, no exclusivity. Contract ends by 31 July 2027.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jul 2026 - Jul 2027

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Jul 31, 2027

Procurement Details

Publication date
05 May 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
308469-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30